InvestorsHub Logo
Followers 13
Posts 901
Boards Moderated 0
Alias Born 03/21/2006

Re: None

Thursday, 01/29/2015 2:33:58 PM

Thursday, January 29, 2015 2:33:58 PM

Post# of 689006
Re CLDX-BMY, BPs have many many trials in progress at any one time. I would not view it as decreasing the possibility of a DCVax-Opdivo combo trial.

It could be viewed as increasing the chances as BMY apparently is choosing combos according to the logic that LP spelled out in the last 2 pres: DCVax activates immune response for all biomarkers in a tumor, thereby increasing the chances of a CI being effective.

The only biomarker off the table with the CLDX combo is CD27.


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News